ISSN 2394-5125
 

Review Article 


A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA.

Abstract
The present review article describes about the newly approved enteral suspension, “DUOPA” by US Food and Drug Administration (FDA) for the new
treatment option for the advanced Parkinson ’s disease with the people having motor fluctuations. This was approved in January 2015. Parkinson
disease foundation’s report state that about 10 million of the people suffering with this advance Parkinson’s disease worldwide. With the several oral
treatment options for this dieses the administered tablets may remain in the stomach too long due to slow and inconsistent emptying of its content
which can delay in the absorption and delayed response to the treatment. But now DUOPA emerged a new trends for the treatment of parkinsonism
with unique route of administration, which bypasses the stomach and enters directly in to small intestine by uses a portable infusion pump that delivers
both the drugs of DUOPA directly in to intestine via a tube up to continuous 16 h. There was no such detailed review available in this area, so this present
article helps the researches and readers to understand about the pathophysiology, and available treatment options for Parkinsonism in attractive
manner and also perceive the significance of use of DUOPA a carbidopa and levodopa enteral suspension with an innovative administration technique.

Key words: Parkinsonism, DUOPA, Enteral suspension, Small intestine.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by PRASENJIT MONDAL
Articles by SHRAVANTHI NANNAPU
Articles by POOJA ADI
Articles by SWAPNA NAREDLA
Articles by HARISH PERUKA
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. JCR. 2016; 3(2): 1-5.


Web Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. http://www.jcreview.com/?mno=302644760 [Access: June 01, 2021].


AMA (American Medical Association) Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. JCR. 2016; 3(2): 1-5.



Vancouver/ICMJE Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. JCR. (2016), [cited June 01, 2021]; 3(2): 1-5.



Harvard Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA (2016) A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. JCR, 3 (2), 1-5.



Turabian Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. 2016. A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. Journal of Critical Reviews, 3 (2), 1-5.



Chicago Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. "A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION." Journal of Critical Reviews 3 (2016), 1-5.



MLA (The Modern Language Association) Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA. "A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION." Journal of Critical Reviews 3.2 (2016), 1-5. Print.



APA (American Psychological Association) Style

PRASENJIT MONDAL, SHRAVANTHI NANNAPU, POOJA ADI, SWAPNA NAREDLA, HARISH PERUKA (2016) A REVIEW ON DUOPA–A NEW ANTIPARKINSONIAN COMBINATION AS ENTERAL SUSPENSION. Journal of Critical Reviews, 3 (2), 1-5.